Context-Dependent Cell Cycle Checkpoint Abrogation by a Novel Kinase Inhibitor by Massey, Andrew J. et al.
Context-Dependent Cell Cycle Checkpoint Abrogation by
a Novel Kinase Inhibitor
Andrew J. Massey*, Jenifer Borgognoni, Carol Bentley, Nicolas Foloppe, Andrea Fiumana, Lee Walmsley
Vernalis (R&D) Ltd., Granta Park, Cambridge, United Kingdom
Abstract
Background: Checkpoint kinase 1 and 2 (Chk1/Chk2), and the Aurora kinases play a critical role in the activation of the DNA
damage response and mitotic spindle checkpoints. We have identified a novel inhibitor of these kinases and utilized this
molecule to probe the functional interplay between these two checkpoints.
Principal Findings: Fragment screening, structure guided design, and kinase cross screening resulted in the identification of
a novel, potent small molecule kinase inhibitor (VER-150548) of Chk1 and Chk2 kinases with IC50s of 35 and 34 nM as well as
the Aurora A and Aurora B kinases with IC50s of 101 and 38 nM. The structural rationale for this kinase specificity could be
clearly elucidated through the X-ray crystal structure. In human carcinoma cells, VER-150548 induced reduplication and the
accumulation of cells with .4N DNA content, inhibited histone H3 phosphorylation and ultimately gave way to cell death
after 120 hour exposure; a phenotype consistent with cellular Aurora inhibition. In the presence of DNA damage induced by
cytotoxic chemotherapeutic drugs, VER-150548 abrogated DNA damage induced cell cycle checkpoints. Abrogation of
these checkpoints correlated with increased DNA damage and rapid cell death in p53 defective HT29 cells. In the presence
of DNA damage, reduplication could not be observed. These observations are consistent with the Chk1 and Chk2 inhibitory
activity of this molecule.
Conclusions: In the presence of DNA damage, we suggest that VER-150548 abrogates the DNA damage induced
checkpoints forcing cells to undergo a lethal mitosis. The timing of this premature cell death induced by Chk1 inhibition
negates Aurora inhibition thereby preventing re-entry into the cell cycle and subsequent DNA reduplication. This novel
kinase inhibitor therefore serves as a useful chemical probe to further understand the temporal relationship between cell
cycle checkpoint pathways, chemotherapeutic agent induced DNA damage and cell death.
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Introduction
Cell cycle checkpoints protect the fidelity of DNA replication
and division and ensure the correct ordering of cell cycle events.
Once the information encoded in DNA is lost, it cannot be
replaced, therefore these pathways are vital for maintaining
genomic integrity and preventing carcinogenesis [1]. There are
several checkpoints regulating cell cycle progression: those that are
activated during the G1-, S- or G2-phase of the cell cycle in
response to DNA damage. This DNA damage can arise either as a
result of endogenous stimuli or through external mechanisms
(including genotoxic stress or chemotherapeutic drugs). In
addition, a second kind of checkpoint, here termed the mitotic
spindle checkpoint, is activated during every cell cycle and only
silenced once all chromosomes are properly attached to a bipolar
spindle and ensures accurate chromosome segregation and
protects against aneuploidy.
DNA damaging agents, such as cisplatin, carboplatin, irinotecan
and doxorubicin, along with ionizing radiation are the mainstays
of cancer therapy. While they have different mechanisms of action,
they all directly or indirectly induce DNA damage thereby
activating DNA damage checkpoints and induce cell cycle arrest in
G1, S, or at the G2-M transition. In mammalian cells, the key
effector proteins are p53 and the checkpoint kinases Chk1 and
Chk2. A large proportion of human cancers exhibit dysregulation
of p53 function (e.g. by p53 mutation or loss of p53 expression)
and therefore are unable to activate transcription of the CDK
inhibitor, p21, which is required for arrest in G1. These human
tumors are thought to be highly reliant on the Chk kinases to
protect them in response to DNA damaging insults [2–4]. Chk1 is
required for the signal evoked by damaged DNA to prevent entry
into mitosis; it is widely assumed that Chk1 inhibitors kill cells by
overriding this constraint allowing entry into a lethal mitosis.
Damage sensors that recognize double strand breaks or protein
complexes that recognize replication stress activate the transduc-
ing kinases ATM and ATR. In turn, these kinases directly activate
the effector kinases Chk1 and Chk2. Chk1 and Chk2 negatively
regulate the Cdc25 family of phosphatases thereby preventing cell
cycle progression as well as directly modulating repair proteins
resulting in increased lesion repair. Chk1 appears to be the crucial
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demonstrated it to be indispensible for the S and G2/M
checkpoints [5]. Chk1 inhibition, therefore, represents a novel
therapeutic strategy to increase the lethality of DNA-damaging
chemotherapeutic drugs in p53 pathway defective cancers.
Abrogation of the remaining intact checkpoint should result in
increased tumor cell death. This ‘‘synthetic lethality’’ approach
should increase the therapeutic index of chemotherapeutic drug as
normal cells remain protected by their functional p53 pathway.
This approach has started to be tested clinically with small
molecule inhibitors of Chk1 (AZD7762, PF-477736, XL844 and
SCH900776) currently undergoing Phase I clinical evaluation in
combination with gemcitabine, irinotecan and cytarabine [6–9].
Recent work has suggested that Chk1 may also be required for the
normal operation of the spindle assembly checkpoint [10], which
may account for the ability of the Chk1 inhibitor PF-477736 to
potentiate the efficacy of docetaxel in xenografts [11].
Spindle checkpoint function and thus accurate mitosis relies on
the Mad proteins Mad1, Mad2 and BubR1, the Bub proteins
Bub1 and Bub3, the mitotic kinases Aurora A and Aurora B, as
well as Chk1 [10,12]. Several antimitotic drugs including the
taxanes and the vinca alkaloids, via their effects on microtubules,
prevent the formation of a normal mitotic spindle, resulting in
spindle checkpoint activation. These agents impose mitotic arrest,
usually leading to apoptosis either in mitosis or, more often, in the
post-mitotic G1-phase following mitotic escape [13].
The Aurora family of Ser/Thr kinases consists of three
members designated Aurora A, B and C, all of which play a
role in mitotic progression [14,15]. All three Aurora kinases are
implicated in cancer development and progression, and their
overexpression is common in a wide variety of human cancers
[16,17]. Aurora kinases have become popular targets for cancer
drug discovery with at least thirteen small molecule inhibitors
currently in Phase I and II clinical evaluation [18,19]. Two of the
molecules that have demonstrated the potential of this approach
are VX680 (MK-0457, Vertex/Merck) and AZD1152 (AstraZe-
neca). Inhibiting Aurora B results in premature exit from mitosis,
failed cytokinesis followed by induction of reduplication (that is the
formation of cells with a .4N DNA content). Histone H3
phosphorylation is a widely used biomarker of Aurora B activity
[20]. Through their ability to induce mitotic checkpoint
malfunction, Aurora kinase inhibitors synergize with agents that
target the mitotic spindle, such as paclitaxel and nocodazole
[21,22].
Using fragment screening, structure guided drug design and
kinase cross screening we have identified VER-150548, a potent
small molecule inhibitor of both Chk1 and Chk2, and Aurora A
and Aurora B kinases. Here we demonstrate that in unperturbed
cells, VER-150548 induced a cellular phenotype consistent with
Aurora kinase inhibition but in the presence of DNA damage, a
Chk1 inhibitor phenotype. We have therefore utilised VER-
150548 as a useful chemical probe to further understand the
interplay between these two signalling pathways and the temporal
factor that determines the predominant cellular signalling
pathway.
Results and Discussion
VER-150548 Inhibits Chk and Aurora kinases
The benzimidazole pyrazoles were originally identified from
fragment screening and elaborated, using structure guided drug
design, as small molecule inhibitors of protein kinases. VER-
Table 1. Structure and in vitro activity of VER-150548.
Kinase
AurA AurB Chk1 Chk2 CDK1 CDK2
IC50 (nM) 101 38 35 34 2800 8000
HCT116 HT29 MDA-MB-468
72 h 120 h 72 h 120 h 72 h 120 h
GI50 (mM) 3.4 0.21 4.6 0.42 0.38 0.30
Values are the average of at least two independent determinations.
doi:10.1371/journal.pone.0013123.t001
Figure 1. Structural rationale for inhibitory activity of VER-
150548. (A) X-ray structure of VER-150548 bound to Chk1 highlighting
key molecule-protein interactions. Only the protein binding site in the
direct vicinity of VER-150548 is shown and the glycine loop has been
hidden for clarity. (B) X-ray crystal structure of VER-150548 (ball and
stick with green carbon atoms) binding to the ATP-binding site of Chk1
(left) or docking binding mode of Aurora A (right). Selected residues are
highlighted: the structurally conserved kinase hinge residues in
magenta, two conserved residues which form apolar contacts above
(alanine) and below (leucine) the aromatic core of VER-150548 in light
blue and the polar residues (orange) lining the solvent exposed ‘‘sugar-
phosphate’’ pocket.
doi:10.1371/journal.pone.0013123.g001
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and inhibited Chk1 and Chk2 with IC50s of 35 and 34 nM. Kinase
cross screening identified VER-150548 as a potent inhibitor of
Aurora A (IC50 101 nM) and Aurora B (IC50 38 nM) kinases
(Table 1). VER-150548 was more than 50-fold selective against
CDK1 and 2. In a larger panel of 45 kinases, VER-150548 at 1 mM
inhibited cTAK1, Src and Syk .70% and AMPK, CAMK2,
CAMK4, FLT3, MARK1, MST2, PDPK1 and RSK1 .90%.
VER-150548 at 1 mM did not inhibit MAPKAPK2, a kinase
implicated as important in DNA damage response checkpoints.
Structural rationale for the inhibition of Chk1 and Aurora
kinases by VER-150548
The structure of the Chk1-VER-150548 complex was obtained by
X-ray crystallography at high resolution (1.9 A ˚), confirming that
VER-150548 inhibits Chk1 by occupying its ATP-binding site
(Figure 1A and B). The Chk1 kinase hinge motif (Glu85-Tyr86-
Cys87) hydrogen-bonds the pyrazolo-benzimidazole moiety of VER-
150548, following a pattern typical of kinase-inhibitor complexes.
The pyrazolo-benzimidazole core is deeply buried in the Chk1
binding site with an excellent overall shape complementarity fit. The
core of VER-150548 is sandwiched between apolar side-chains
Ala36 and Leu137, and the methyl substituent of the pyrazole fits
snugly against the gatekeeper residue (Leu84). Burial of this
apolar surface area is expected to be a major contributing factor
to the potency of VER-150548 for Chk1. The piperidine of VER-
150548 binds in the solvent exposed periphery of the binding site,
which would normally accommodate the sugar-phosphate of
ATP. Thus, the structural elements underpinning the binding
of VER-150548 to Chk1 are precisely defined, allowing the
modeling with high confidence of the binding mode in similar
kinase ATP-binding sites. The binding mode of VER-150548 in
Aurora A was modeled based on the crystal structures of close
analogues of VER-150548 bound to this kinase allowing the
placing of VER-150548 with a high degree of certainty. There is
an overall shape similarity between the ATP-binding sites of
Chk1 and Aurora A (Figure 1B). Many conserved structural
features exist between these two binding clefts, including the
geometry of the kinase hinge backbone, the same gatekeeper side-
chain (leucine), several apolar residues contacting the pyrazolo-
benzimidazole core, and the more polar character of the
peripheral pocket accommodating the piperidine moiety. The
overall complementarity of shape and chemical interactions
observed between VER-150548 and Chk1 is largely conserved in
Figure 2. VER-150548 induces polyploidy and inhibits Histone H3 Ser10 phosphorylation in HT29 cells. (A) HT29 cells were exposed to
the indicated concentrations of VER-150548 for 8, 24 or 48 hours. Cell cycle profiles were determined by propidium iodide staining on a FACSArray
cytometer. (B) HT29 cells were exposed to the indicated concentrations of VER-150548 for 24 hours. Cell lysates were prepared and the level of pH3
(Ser10) determined by western blotting.
doi:10.1371/journal.pone.0013123.g002
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inhibitor of these two kinases.
VER-150548 Inhibits Aurora Kinases in Human Carcinoma
Cells
Inhibition of Aurora kinases results in cell death after extended
time periods. VER-150548 inhibited the proliferation of human
cancer cell lines with GI50s in the range 0.38–4.6 mM following
72 hour treatment (Table 1). The potency increased in line with
extended incubation times; GI50s were in the range 0.21–0.42 mM
after 120 hour incubation.
siRNA mediated knockdown of Aurora B or addition of Aurora
B kinase inhibitors results in failed cytokinesis, which is followed by
the onset of DNA replication in cells that already have a 4N DNA
content [23]. Flow cytometry was utilized to evaluate the ability of
VER-150548 to induce reduplication and inhibit Histone H3
phosphorylation in carcinoma cells. Treatment with 200 nM or
greater VER-150548 resulted in accumulation of cells with a 4N
DNA content after 8 to 24 hours, which we tentatively attribute to
arrest at the G2/M transition following Aurora A inhibition
(Figure 2A) [24]. Longer incubations led to a greatly increased
number of cells with 8N DNA content indicating that the
compound blocked cell division without preventing chromosomal
DNA replication. The Aurora kinase inhibitor VX680 [25]
similarly caused G2/M arrest at early time points and subsequent
reduplication following extended incubation. VER-150548 in-
duced reduplication in HCT116 and MDA-MB-468 cells at
concentrations comparable to those that induced reduplication in
HT29 cells (data not shown). Aurora B is responsible for most of
the kinase activity directed against Histone H3 on serine 10 (pH3
(Ser10)), hence phosphorylation at this site can be employed as a
biomarker of Aurora B kinase activity [26]. VER-150548 induced
a decrease in pH 3 (Ser10) levels in asynchronous HT29 cells
(Figure 2B), though slightly higher concentrations of VER-150548
were required to reduce pH 3 (Ser10) levels than were necessary to
induce reduplication.
VER-150548 Abrogates Cell Cycle Checkpoints
The checkpoint kinase Chk1 is essential for arresting the cell
cycle of p53 defective cells in response to DNA damage [5]
Figure 3. VER-150548 abrogates the DNA damage checkpoint induced by gemcitabine, camptothecin or cisplatin. (A) HT29 cells were
exposed to gemcitabine (25 nM) for 16 hours followed by increasing concentrations of VER-150548 in the presence of nocodazole for 24 hours.
Mitotic cells were determined following staining for pH3 (Ser10) and counterstaining with DAPI. Values are the average of four independent
determinations 6 SD. (B) HT29 cells were treated with gemcitabine (Gem, 25 nM), camptothecin (CPT, 50 nM) or cisplatin (CP, 12 mM) for 16 hours
followed by 0 (-) or 100 nM (+) VER-150548 in the presence of nocodazole for 24 hours. Cell lysates were prepared and analyzed by western blotting.
(C) HT29 cells were treated with gemcitabine (Gem, 25 nM), for 16 hours followed by 0 to 800 nM VER-150548 in the presence of nocodazole for
24 hours. Cell lysates were prepared and analyzed by western blotting.
doi:10.1371/journal.pone.0013123.g003
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PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13123Figure 4. Cell cycle changes induced by checkpoint abrogation by VER-150548. (A) HT29 cells were mock treated with DMSO or exposed
to gemcitabine for 16 hours followed by VER-150548 for a further 24 or 48 hours. (B) HT29 cells were mock treated with DMSO or exposed to
gemcitabine, camptothecin or cisplatin for 16 hours followed by DMSO, VER-150548 (200 nM), PF-477736 (400 nM), VX680 (400 nM) or a
combination of PF-477736 and VX680 for a further 48 hours. Fixed cells were analyzed by flow cytometry.
doi:10.1371/journal.pone.0013123.g004
Novel Checkpoint Inhibitor
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as gemcitabine and cisplatin. The ability of VER-150548 to
abrogate gemcitabine induced S-phase arrest was determined in
p53-defective HT29 cells. Following treatment with gemcitabine
then VER-150548 plus nocodazole, cells were examined for
expression of pH 3 (Ser10); a marker indicative of mitosis.
Nocodazole arrests cells in mitosis whilst gemcitabine, in com-
bination with nocodazole, results in S-phase arrest with a low
proportion of pH 3 (Ser10) positive mitotic cells. VER-150548
abrogated gemcitabine induced S-phase arrest leading to the
accumulation of cells in mitosis with an EC50 of 23 nM
(Figure 3A). Gemcitabine, camptothecin or cisplatin arrested
HT29 cells in either S- or G2-phase (as evidenced by high pCdc2
(Tyr15) and low MPM-2, pPP1a (Thr320) and pH 3 (Ser10)
levels). This cell cycle arrest could be abrogated by VER-150548,
allowing cells to progress through into mitosis and subsequent
trapping by nocodazole (Figure 3B). Checkpoint abrogation
occurred at concentrations of VER-150548 as low as 100 nM.
At higher concentrations (.400 nM), a decrease in mitotic
markers was observed reflecting the Aurora kinase inhibitory
activity of the molecule (Figure 3C). DNA damage induced
checkpoint abrogation appeared reliant on the absence of
functional p53 as no checkpoint abrogation was observed in the
p53 proficient colon carcinoma cell line HCT116 (Figure S2).
Abrogation of DNA damage induced cell cycle checkpoints by
VER-150548 resulted in rapid cell death, as confirmed by the
large increase in cells with a DNA content ,2N after 24 and
48 hours (Figure 4A). Cell death occurred in a dose and time
dependent fashion with the greatest cell death occurring after
48 hours. The Chk1 inhibitor PF-477736 [7] similarly abrogated
DNA damage induced cell cycle arrest whilst the Aurora inhibitor
VX680 [25] was unable to override the DNA damage induced
arrest (Figure 4B). Combination treatment of camptothecin or
cisplatin with VER-150548 resulted in a small fraction (,17%) of
cells with a DNA content .4N (Figure 4B and 5A). This was
noticeably less than those cells treated with VER-150548 alone
(63% DNA content .4N). The combination treatment induced a
DNA content between 4 and 7N and this did not match the 8N
DNA profile expected from reduplication following Aurora
inhibition. Similarly, in cells treated with DNA damaging agents
followed by PF-477736 plus VX680, only a small percentage had a
DNA content .4N (11–15%). Again the DNA content of this
fraction of cells varied from 4N to around 7N and did not
correspond with the 8N predicted from reduplication. Hoescht
nuclear staining of cells treated with camptothecin plus VER-
150548 or PF-477736 indicated a high degree of cells with
aberrant nuclear morphology indicative of a high degree of
chromosomal abnormalities and damage (Figure 5B).
An additional checkpoint, the spindle assembly checkpoint,
monitors the proper alignment of chromosomes during mitosis and
can be activated by anti-mitotic drugs such as paclitaxel. Treatment
of paclitaxel arrested HT29 cells with VER-150548 or VX680
resulted in spindle checkpoint malfunction and the exiting of cells
from mitosis (Figure 6). Twenty four hours after the removal of
paclitaxel, 65.4% of cells remained arrested in G2 or M compared
to 34.3 and 28.5% treated with 200 nM VER-150548 or 400 nM
VX680 respectively. Microscopic analysis of combination treated
cells indicated a return to an interphase morphology whilst those
treated with DMSO maintained a mitotic morphology (Figure 6).
Checkpoint Abrogation Potentiates DNA Damage and
Cell Death
Following DNA damage, the histone variant H2AX is
phosphorylated on Ser139 by ATM/ATR and forms nuclear foci
at the sites of damage thereby serving as a useful marker of cellular
levels of DNA damage. Inhibition of checkpoint kinases following
cytotoxic chemotherapy results in increased DNA strand breaks
due to stalled replication fork collapse and replication of damaged
DNA. In addition to phosphorylating H2AX, ATM/ATR also
phosphorylates Chk1 at Ser345. Treatment of HT29 cells with
gemcitabine, camptothecin or cisplatin for 40 hours increased
pChk1 (Ser345) and, to a lesser extent, pH2AX (Ser139). The
sequential treatment of HT29 cells with a DNA damaging agent
for 16 hours followed by VER-150548 for a further 24 hours
resulted in a decrease in pChk1 (Ser345) but a large increase in
pH2AX (Ser139) (Figure 7A). Abrogation of gemcitabine induced
arrest resulted in the rapid formation of DNA strand breaks as
visualized by the phosphorylation of Chk1 at Ser345 within 1 hour
and H2AX at Ser139 within 6 hours (Figure 7B). H2AX
phosphorylation was maintained up to 24 hours after the addition
of VER-150548. In contrast, Chk1 was dephosphorylated after
6 hours resulting in a complete loss of Ser345 phosphorylation by
24 hours. A washout experiment confirmed that 6 hour exposure
Figure 5. Checkpoint abrogation does not result in reduplica-
tion. (A) The fraction of cells with a DNA content .4N was quantitated
from the cell cycle profiles in Figure 4. (B) HT29 cells were treated with
camptothecin for 16 hours followed by DMSO, VER-150548 (200 nM) or
PF-477736 (400 nM) for a further 48 hours. Following fixation with
paraformaldehyde, nuclei were stained with Hoescht 33342 and imaged
at 4006magnification using a Zeiss Axiovert microscope.
doi:10.1371/journal.pone.0013123.g005
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PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13123Figure 6. VER-150548 abrogates Paclitaxel induced mitotic arrest. HT29 cells were treated with 100 nM paclitaxel for 18 hours, media
removed and treated with VER-150548 (200 nM) or VX680 (400 nM) for a further 24 hours before being either fixed and analyzed by flow cytometry
or visualized under a Zeiss Axiovert microscope at 2006magnification.
doi:10.1371/journal.pone.0013123.g006
Figure 7. Checkpoint abrogation increases DNA damage. (A) HT29 cells were treated with gemcitabine, camptothecin or cisplatin for 16 hours
followed by 0 (-) or 100 nM (+) VER-150548 for 24 hours. (B) HT29 cells were treated with or without gemcitabine for 16 hours followed by VER-
150548 (100 nM) for the indicated times. (C) HT29 cells were exposed to gemcitabine followed by VER-150548 (100 nM). At the indicated time points,
drug containing media was removed and replaced with drug free. All cells were harvested 24 hours post the addition of VER-150548 and the
indicated proteins analyzed by western blotting. All lanes were from the same gel and experiment; irrelevant lanes have been removed for clarity.
doi:10.1371/journal.pone.0013123.g007
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and that this was maintained for at least 18 hours after the
removal of VER-150548 (Figure 7C).
Chk1 inhibitors potentiate the growth inhibitory activity of a
variety of chemotherapeutic agents in p53 defective cancer cells
[6,7]. VER-150548 potentiated the growth inhibitory activity of
gemcitabine, cisplatin, camptothecin and doxorubicin in p53
mutant HT29 cells (Figure 8A and B). The range of concentrations
at which VER-150548 enhanced gemcitabine and camptothecin
cytotoxicity was substantial: robust potentiation was observed
between 50 and 400 nM VER-150548 and correlated closely with
increased DNA damage. In common with other Chk inhibitors,
the greatest potentiation was observed when VER-150548 was
combined with gemcitabine [6,7]. As expected, this potentiation
was dependent on p53 status; VER-150548 did not potentiate the
growth inhibitory activity of any of these agents in p53 wild-type
HCT116 cells.
Fragment screening and structure guided drug design identified
VER-150548 as a novel, potent small molecule inhibitor of Chk
and Aurora kinases. In unperturbed human carcinoma cell lines,
VER-150548 induced reduplication and inhibited Histone H3
phosphorylation on serine 10, a phenotype consistent with Aurora
kinase inhibition in cells. In cells treated with a variety of DNA
damaging agents, VER-150548 abrogated both S-phase and G2/
M-phase arrest induced by these agents. This abrogation of cell
cycle arrest was coupled with the potentiation of cell killing by
gemcitabine, camptothecin, cisplatin and doxorubicin in p53
defective but not proficient tumor cells. As with other Chk1
inhibitors such as AZD7762 and PF-477736, the greatest
potentiation was observed with gemcitabine [6,7]. In this case,
not only did VER-150548 potentiate the growth inhibitory effect
of gemcitabine but increased the fraction of cells killed by this
antimetabolite. This increased cell killing was accompanied with
an increase in pH2AX (Ser139) levels and suggests that this
elevated cytotoxicity is due to greater levels of DNA damage
following checkpoint abrogation. The additional stimuli of DNA
damage resulted in a cellular phenotype consistent with Chk1
inhibition that was not repressed by activity against the Aurora
kinases. Aurora kinase activity would therefore appear dispensable
for DNA damage checkpoint abrogation and subsequent poten-
tiation of cytotoxic chemotherapy. Conversely, inhibition of
Aurora kinases does not activate a Chk1 dependent DNA damage
response and Chk1 activity is not necessary for inducing
polyploidy following Aurora inhibition. Checkpoint inhibition is
accepted to result in a lethal mitosis due to cells attempting to
undertake cell division with extensive chromosomal damage. Since
Aurora kinase inhibition prevents the successful conclusion of
cytokinesis and cell division, completion of mitosis is not necessary
for mitotic catastrophe in cells carrying extensive DNA damage.
Following treatment with a DNA damaging agent, VER-150548
appeared no longer able to induce reduplication and polyploidy in
p53 proficient or deficient human carcinoma cells. Treatment with
camptothecin or cisplatin plus VER-150548 resulted in the
identification of a small fraction (around 10–15%) of cells with a
DNA content between 4 and 7N. A closer microscopic analysis of
these cells indicated a high number o fc e l l sw i t ha na b e r r a n tn u c l e a r
morphology that is highly suggestive of chromosomal abnormalities
and damage. Therefore it is not clear if these cells have escaped
mitotic catastrophe, bypassed cytokinesis and attempted S-phase with
an incomplete complement of chromosomes or have undergone
asymmetrical cell division. A similar phenotype was also observed
when camptothecin or cisplatin treated cells were subsequently
exposed to a combination of the Chk1 inhibitor PF-477736 and the
Aurora inhibitor VX680. The generation of this sub-population of
cells with a DNA content between 4 and 7N was dependent on the
presence of DNA damage and inhibition of Chk1 kinase, and
increased when Aurora kinases were also inhibited. These results are
consistent with a small sub-population of cells that have escaped
mitotic catastrophe, failed cytokinesis due to Aurora kinase inhibi-
tion and attempted S-phase with an incomplete complement of
chromosomes. Attempting to replicate extensively damaged DNA in
this subsequent S-phase results in further cell death.
Inhibiting Chk1 and Aurora kinases in the presence of DNA
damage resulted in a cellular response predominated by the Chk1
inhibitory activity of VER-150548. Why do cells fail to undergo
reduplication following treatment with the combination of DNA
damaging cytotoxic chemotherapy and our novel kinase inhibitor?
We would like to suggest that the temporal arrangement of these
two signaling pathways and the timing of response are critical to
Figure 8. VER-150548 potentiates the cytotoxic activity of
chemotherapeutic drugs in HT29 colon carcinoma cells. (A)
HT29 cells were co-treated with gemcitabine (top) or camptothecin
(bottom) in the absence (circles) or presence (squares) of VER-150548
(100 nM) for 72 hours. Example curves are illustrated. (B) Potentiation
factors (Pf) were calculated as GI50(cytotoxic agent alone)/GI50(combination treatment)
for VER-150548 in combination with various chemotherapeutic agents.
Values are the average of four independent determinations.
doi:10.1371/journal.pone.0013123.g008
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large quantities of potentially lethal DNA damage following
treatment with a cytotoxic chemotherapeutic agent, inhibition of
the Chk1 kinase relieves cell cycle arrest allowing these cells to
enter mitosis. The large quantity of DNA damage sustained by
these cells due to checkpoint abrogation results in mitotic
catastrophe and subsequent cellular death from this mitosis. This
occurs prior to Aurora kinase inhibition, cytokinesis failure and
subsequent reduplication. The small fraction of cells escaping this
lethal mitotic event will fail cytokinesis due to Aurora kinase
inhibition and attempt DNA replication with heavily damaged
DNA. This is again likely to be highly lethal. An alternative
explanation for the absence of DNA reduplication in the presence
of a DNA damaging drug could be that the DNA damage inflicted
by the cytotoxic chemotherapeutic drugs inhibits DNA synthesis
preventing the subsequent full re-replication of the genome. This
would result in cell cycle arrest at this subsequent S-phase. Since
the checkpoint kinase Chk1 will still be inhibited by VER-150548,
this S-phase arrest would need to occur via a Chk1 independent
checkpoint. Our data is much more consistent with the induction
of cell death as observed by the massive increase in cells with a
sub-G1 DNA content prior to DNA re-replication rather than
inhibition of DNA synthesis. Therefore in cells harboring large
amounts of potentially lethal DNA damage, inhibition of Chk1
results in cellular death prior to Aurora kinase inhibition thereby
preventing DNA reduplication and polyploidy. The temporal
arrangement of these two signaling pathways thereby defines
why the Chk1 cellular phenotype predominates over the Aurora
phenotype in cells treated with cytotoxic chemotherapeutic agents.
In summary, we have identified a relatively non-specific small
molecule inhibitor of Chk and Aurora kinases. In unperturbed
cells, the Aurora phenotype predominated suggesting that
Aurora B is a relatively ‘easy’ kinase to inhibit with the cellular
EC50 approximating that of the 120 hour GI50. At lower doses
and in the presence of a DNA damaging agent, the molecule
behaves as a Chk1 inhibitor. The temporal arrangement and
time to effect of these two signalling pathways thereby deter-
mines the signalling network and therefore the cellular pheno-
type that predominates.
Methods
In vitro Kinase Assays
Kinase assays were performed as previously described [27]. Details
of the assay conditions for each kinase are described in Table 2.
Cell Culture and Cytotoxicity Assay
All cells were obtained from the American Type Culture
Collection and cultured in DMEM containing 10% FCS
(Invitrogen). The cytotoxicity of VER-150548 was determined
following exposure of cells in 96 well plates to a 10-point titration
for 72 or 120 hours. Cell proliferation was determined using a
CellTiter-GloH Luminescent Cell Viability Assay kit (Promega).
Mitotic Index Assay
HT29 cells were seeded in 96 well plates and treated with 25 nM
gemcitabine for 16 hours to induce S-phase arrest. Increasing
concentrations of VER-150548 were added in the presence of
0.5 mMnocodazoleforafurther24 hoursbeforefixing cellswith4%
formaldehyde. Mitotic index was determined following cell staining
with a phospho-H3 polyclonal antibody and DAPI (Invitrogen).
Mitotic cells were scored with a Zeiss Axiovert microscope.
Antibodies and Western Blotting
Antibodies against the following proteins/epitopes were ob-
tained from the indicated supplier: MPM-2 (ab14581) from
Abcam; pHistone H3 (Ser10, 32219) from Millipore; and pPP1a
(Thr320, #2581), pChk1 (Ser345, #2341), pCdc2 (Tyr15, #9111)
and pH2AX (Ser139, #2577) from Cell Signaling Technologies.
Treated and untreated cells were washed once with PBS and lysed
in 50 mM Tris-pH6.8, 2% SDS, protease inhibitor cocktail
(Roche) and boiled for 5 minutes. Protein concentration was
determined using BCA kit (Pierce). Equal amounts of lysate were
separated by SDS-PAGE and western blot analysis conducted
using the antibodies indicated above.
Flow Cytometry
HT29 cells were seeded in 6-well plates and subsequently
treated with the indicated concentrations of cytotoxic agent or
VER-150548 for 8–48 hours. All cells were harvested, fixed in
70% ethanol and stained with propidium iodide/RNase A. Cell
cycle profiles were examined by flow cytometry using a
FACSArray cytometer (BD) and FACSDiva software (BD).
Potentiation Assays
HT29 cells were seeded in 96-well plates and treated with a 10-
point titration of gemcitabine, camptothecin, cisplatin or doxoru-
bicin in the presence of a fixed concentration of VER-150548 for
72 hours. Cell proliferation was determined using a CellTiter 96
AQueous One Solution Cell Proliferation Assay (MTS, Promega).
Table 2. In vitro kinase assay conditions.
Kinase
Aurora A Aurora B CDK1/CycB CDK2/CycA Chk1 Chk2
Supplier Invitrogen Invitrogen Invitrogen Vernalis Invitrogen Invitrogen
Cat No. PV3612 PV3970 PV3292 PV3040 PV3367
[Enzyme] (nM) 8 15 52 57 12.5 5
Cofactors 0.02 mM INCENP
[ATP] (mM) 10 25 100 100 100 100
Peptide Kemptide PAKtide Histone H1 CDKtide CHKtide CHKtide
Sequence LRRASLG RRRLSFAEP Millipore 14-155 HATTPKKKRK KKKVSRSGLYRSPSMPENLNRPR KKKVSRSGLYRSPSMPENLNRPR
Incubation time
(mins)
30 60 40 40 40 40
doi:10.1371/journal.pone.0013123.t002
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Supporting Information
Figure S1 Chemical structure of VER-150548.
Found at: doi:10.1371/journal.pone.0013123.s001 (0.04 MB TIF)
Figure S2 VER-150548 does not abrogate gemcitabine or
camptothecin induced cell cycle arrest in p53 proficient
HCT116 cells. HCT116 cells were mock treated with DMSO or
exposed to gemcitabine or camptothecin or for 16 hours followed
by DMSO or VER-150548 (200 nM) for a further 24 or 48 hours.
Fixed cells were analyzed by flow cytometry.
Found at: doi:10.1371/journal.pone.0013123.s002 (0.24 MB TIF)
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